Avutometinib Potassium; Defactinib Hydrochloride Patent Expiration
Avutometinib Potassium; Defactinib Hydrochloride was first introduced by Verastem Inc
Avutometinib Potassium; Defactinib Hydrochloride Patents
Given below is the list of patents protecting Avutometinib Potassium; Defactinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Avmapki Fakzynja Co-pack (copackaged) | US11873296 | Solid forms of a dual RAF/MEK inhibitor | Dec 29, 2042 | Verastem Inc |
| Avmapki Fakzynja Co-pack (copackaged) | US11517573 | Therapeutic compositions, combinations, and methods of use | Sep 11, 2040 | Verastem Inc |
| Avmapki Fakzynja Co-pack (copackaged) | US11400090 | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder | Oct 29, 2038 | Verastem Inc |
| Avmapki Fakzynja Co-pack (copackaged) | US7928109 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Aug 21, 2029 | Verastem Inc |
| Avmapki Fakzynja Co-pack (copackaged) | US8247411 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Apr 17, 2028 | Verastem Inc |
| Avmapki Fakzynja Co-pack (copackaged) | US7897792 | Coumarin derivative having antitumor activity | Feb 09, 2027 | Verastem Inc |
Avutometinib Potassium; Defactinib Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List